Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Griffith’s Compounding Draft Ties FDA Inspections To State Reporting

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Griffith circulates a discussion draft with new procedures for states to tell FDA when they have found problems at a compounder, but only then could the agency inspect the facility.

You may also be interested in...



Compounding Bill In Senate Gets Bipartisan Push For Floor Vote

HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.

Compounding: How Does FDA Expand Oversight Without Legislation?

After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.

Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says

KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel